Central sleep apnea in congestive heart failure: prevalence, mechanisms, impact, and therapeutic options
- PMID: 16052417
- DOI: 10.1055/s-2005-864206
Central sleep apnea in congestive heart failure: prevalence, mechanisms, impact, and therapeutic options
Abstract
Heart failure due to left ventricular systolic dysfunction is a prevalent syndrome and associated with morbidity, mortality, and huge economic cost. According to reports from several laboratories, a large number of patients with heart failure have central sleep apnea. Central sleep apnea causes arousals and sleep disruption, alters blood gases, and increases sympathetic activity. The pathophysiological consequences of central sleep apnea could adversely affect left ventricular structure and functions and worsen prognosis of heart failure. Several treatment options, including use of nocturnal supplemental oxygen, positive airway pressure devices, and theophylline have been systematically studied and have been shown to improve central sleep apnea. Long-term studies, however, are necessary to determine the impact of therapy on natural history of left ventricular systolic dysfunction.
Similar articles
-
Treatment of central sleep apnea in heart failure.Sleep. 2000 Jun 15;23 Suppl 4:S224-7. Sleep. 2000. PMID: 10893108 Review.
-
[Sleep apnea syndromes and cardiovascular disease].Bull Acad Natl Med. 2005 Mar;189(3):445-59; discussion 460-4. Bull Acad Natl Med. 2005. PMID: 16149210 Review. French.
-
Suppression of central sleep apnea by continuous positive airway pressure and transplant-free survival in heart failure: a post hoc analysis of the Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure Trial (CANPAP).Circulation. 2007 Jun 26;115(25):3173-80. doi: 10.1161/CIRCULATIONAHA.106.683482. Epub 2007 Jun 11. Circulation. 2007. PMID: 17562959 Clinical Trial.
-
Central sleep apnea-hypopnea syndrome in heart failure: prevalence, impact, and treatment.Sleep. 1996 Dec;19(10 Suppl):S229-31. Sleep. 1996. PMID: 9085518
-
Autonomic abnormalities in congestive heart failure patients with sleep-disordered breathing.J Card Fail. 2007 Jun;13(5):395-400. doi: 10.1016/j.cardfail.2007.02.003. J Card Fail. 2007. PMID: 17602987 Review.
Cited by
-
Effects of Sacubitril-Valsartan on Clinical, Echocardiographic, and Polygraphic Parameters in Patients Affected by Heart Failure With Reduced Ejection Fraction and Sleep Apnea.Front Cardiovasc Med. 2022 Apr 5;9:861663. doi: 10.3389/fcvm.2022.861663. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35449875 Free PMC article.
-
Prevalence and treatment of breathing disorders during sleep in patients with heart failure.Curr Treat Options Cardiovasc Med. 2005 Aug;7(4):295-306. doi: 10.1007/s11936-005-0040-0. Curr Treat Options Cardiovasc Med. 2005. PMID: 16004860
-
Sleep and health-related quality of life in heart failure.Congest Heart Fail. 2009 Sep-Oct;15(5):228-33. doi: 10.1111/j.1751-7133.2009.00106.x. Congest Heart Fail. 2009. PMID: 19751424 Free PMC article.
-
Multimodal brain imaging investigation of self-reported sleep quality and daytime sleepiness in older adults with heart failure.Int J Neurosci. 2018 Nov;128(11):1044-1051. doi: 10.1080/00207454.2018.1475374. Epub 2018 May 28. Int J Neurosci. 2018. PMID: 29745279 Free PMC article.
-
Prevalence of Obstructive Sleep Apnea Using Home Sleep Test in Taiwan During the Coronavirus Disease Pandemic.Nat Sci Sleep. 2023 Dec 22;15:1107-1116. doi: 10.2147/NSS.S434278. eCollection 2023. Nat Sci Sleep. 2023. PMID: 38149042 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical